anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lean patients with NAFLD may develop cardiac complications independently of pre-existent metabolic disruptions and comorbidities. To address the underlying mechanisms independent of the development of obesity, we used a murine model of hepatic mitochondrial deficiency. The liver-heart axis was studied as these mice develop microvesicular steatosis without obesity. Our results unveil a sex-dependent phenotypic remodeling beyond liver damage. Males, more than females, show fasting hypoglycemia and increased insulin sensitivity. They exhibit diastolic dysfunction, remodeling of the circulating lipoproteins and cardiac lipidome. Conversely, females do not manifest cardiac dysfunction but exhibit cardiometabolic impairments supported by impaired mitochondrial integrity and β-oxidation, remodeling of circulating lipoproteins and intracardiac accumulation of deleterious triglycerides. This study underscores metabolic defects in the liver resulting in significant sex-dependent cardiac abnormalities independent of obesity. This experimental model may prove useful to better understand the sex-related variability, notably in the heart, involved in the progression of lean-NAFLD.
Breakthrough bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC.

Women who are not pregnant and use Natazia, may experience amenorrhea. Based on patient diaries, amenorrhea occurs in approximately 16% of cycles in women using Natazia. Pregnancy should be ruled out in the event of amenorrhea occurring in two or more consecutive cycles. Some women may encounter amenorrhea or oligomenorrhea after stopping COCs, especially when such a condition was pre-existent.

Based on patient diaries from three clinical trials evaluating the safety and efficacy of Natazia for contraception, 10-23% of women experienced intracyclic bleeding per cycle.
The purpose of this study is to characterize the ocular safety and tolerability, the systemic safety and tolerability, and the pharmacokinetic profile of repeat doses of a higher strength ophthalmic formulation of pazopanib, 10 mg/mL. The higher strength formulation provides an opportunity to increase the total daily dose of pazopanib administered. In this 3-cohort study, healthy adult volunteers will participate in one 14-day repeat-dose session (plus a single dose on day 15), randomized to receive either pazopanib eye drops or placebo. Subjects in cohort 1 will receive 1 drop four times daily for a calculated total daily dose of 1.6 mg. The dosage regimen for two subsequent cohorts will be determined based on the emerging safety profile. The Japanese population chosen for the third cohort will provide a safety and tolerability profile as well as the pharmacokinetic profile of pazopanib prior to further development of this formulation in Japanese patients with AMD.
125 nurses from the clinic and intensive care units, who received the most intensive blood transfusion from two different hospitals, were included in the study as the intervention and control groups. The control group was not trained. Only the pretest was administered one week after the posttest. After the pre-test was applied to the nurses in the intervention group, five modules of training, which lasted four hours, were given using interactive methods. Five modules of training were prepared by the researcher. These five modules are the 1st module of training; definition of hemovigilance, its aims, the development of hemovigilance in the world and in Turkey, and legal legislation, Module 2; Donor selection, Blood donation Process, Phlebotomy and Donor reactions, Module 3; blood, blood transfusion, its purpose, properties of blood and blood components, Blood transfusion process, Module 4; acute and delayed transfusion reactions and management, Module 5; It consists of the national hemovigilance system, the organization of the hemovigilance system at the hospital level, Traceability, Trace-back from the Patient to the Donor, and Look-back from the Donor to the Patient. the training was over, the final test was administered. One month later, this test was repeated.
This group is composed of PD patients with motor complications of more than 3 years. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
FIELD: organic chemistry, medicine, oncology, pharmacy. SUBSTANCE: invention relates to a novel cryptoficine compound of the formula (I)   where Ar means methyl or phenyl or any simple unsubstituted or substituted aromatic or heterocyclic group; R 1  means halogen atom; R 2  means OH; or R 1  and R 2  can be joined to form epoxy-ring, aziridine ring; R 1  and R 2  can be joined in common to form a double bond between C 18  and C 19 ; R 3  means lower alkyl group; R 4  and R 5  mean H; or R 4  and R 5  can be joined to form a double bond between C 13  and C 14 ; R 6  means benzyl, hydroxybenzyl (oxybenzyl), alkoxybenzyl, halogenoxybenzyl, dihalogenoxybenzyl, halogenalkoxy-benzyl or dihalogenalkoxybenzyl group; R 7 , R 8 , R 9 , R 10  each means independently H or lower alkyl group; X and Y each means independently O, NH. Compounds can be used for inhibition of proliferation of cells in mammal and for treatment of tumors. Invention describes also pharmaceutical composition based on compounds and methods of using. EFFECT: improved method of treatment, valuable medicinal properties of compounds. 56 cl, 10 tbl, 14 dwg, 22 ex
1. Rationale: Oxytocin (OT) is a neuropeptide produced in the supraoptic and paraventricular nuclei of the hypothalamus. There exists at least three plausible mechanisms through which OT may decrease pain sensitivity. In brief, the first mechanism involves spinal signaling. A direct hypothalamo-spinal projection originating from the paraventricular nucleus transports OT, to the dorsal horn (Lamina-I, II, and IV), an area containing OT receptors that influence glutamate and GABA cellular signaling. The second mechanism involves an indirect pathway via the endogenous opioids. Evidence suggests that OT binds to opioid receptors and may also stimulate endogenous opioid release in the brain. Finally, OT may decrease pain by improving mood, decreasing anxiety, and mitigating the stress response.

   Thirty-three animal investigations have assessed OT-pain relationships with 29 reporting that exogenous administration and higher endogenous levels decreased pain. There is a lack of clarity of an OT-pain association in the human literature due to a paucity of methodologically rigorous trials. Thus far, OT administration has been reported to lower pain sensitivity among patients experiencing chronic back pain, headache, constipation, and colon pain. To date, no research has evaluated the association between intranasal OT and chronic pelvic pain. The association between OT and pain may be different in women with pelvic pain relative to other chronic pain conditions because of a potential peripheral OT-pain pathway. There is an abundance of OT receptors in the uterus, and OT is a potent uterogenic agent that is clinically used in large doses to stimulate uterine contractions and induce labor. While OT does not cross the blood-brain-barrier, the central administration of intranasal OT increases central and blood-plasma OT concentrations. Thus, intranasal OT administration may be associated with pain through central and peripheral pathways; however uterine contractions with 24IU doses of intranasal OT occur in only 1 in every 100-1000 people.
2. Research questions and objectives: This research is a pilot study of the efficacy of intranasal OT at improving pain and function among women with chronic pelvic pain of primarily musculoskeletal origin.
3. Design: This study will utilize a double-blind, placebo-controlled, within-subjects crossover design. Participants will complete 6-weeks of testing consisting of two 2-week intranasal administrations separated by a 2-week washout period
A medical tube for putting into a human organ and electrically connected to a blockchain network is disclosed. The medical tube includes a tube, a chipset and an environment-inside body detection module. The tube includes a first end and a second opposite to each other. The first end is placed in the human organ. The second end is placed outside the human body. The chip set is located on the first end and including a blockchain tracer for recording a transportation history of the medical tube in the blockchain network for tracing. The environment-inside body detection module is located on the first end.
This is a 2-part study. Part 1 of the study will compare the PK of ACP-196 in participants with mild hepatic insufficiency (a score of 5 to 6, on the Child-Pugh scale) and moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale) to healthy (mean) matched control participants for age and weight. Part 2 of the study, if it is conducted, will compare the PK of ACP-196 in participants with severe hepatic insufficiency (a score of 10 to 15 on the Child-Pugh scale) to the healthy control participants from Part 1. In Part 1, 6 participants with mild hepatic insufficiency, 6 participants with moderate hepatic, and 6 healthy control participants matched to the hepatic insufficiency groups according to mean age and mean weight will be enrolled. In Part 2, if conducted, 6 participants with severe hepatic insufficiency will be enrolled. The control group of Part 1 will be used for Part 2 PK comparison. Participants will be screened within 28 days before the dose. Participants will be contacted approximately 14 days after the last dose of study drug administration to determine if any adverse event has occurred since the last dose of study drug.
Patients that were deemed admissible to the trial received 1 intra-articular injection of autologous conditioned serum (Orthokine®) for 4 consecutive weeks at the site of OA. These patients were then followed at 1 month and 6 months for clinical and functional evaluation using VAS for pain, WOMAC, and KSS.
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension, equivalent to 10 mg hydrocodone bitartrate and 8 mg chlorpheniramine maleate per 5 mL, is a yellow viscous suspension, available as:

NDC 27808-086-01 4 fl. oz. bottle containing 115 mL suspension.  
NDC 27808-086-03 3 fl. oz. bottle containing 70 mL suspension.  
Each bottle is supplied with a dosing cup calibrated for measuring 2.5 mL and 5 mL doses.  
Shake well. Dispense entire bottle as one unit.

NDC 27808-086-02 16 fl. oz. bottle containing 473 mL suspension.  
Shake well. Dispense in a tight, light-resistant container, as defined in the USP, with a child-resistant closure.

Light Sensitive: Protect from light. Store away from direct sunlight.

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature.]

Ensure that patients have an oral dosing dispenser that measures the appropriate volume in milliliters. Counsel patients on how to utilize the oral dosing dispenser and correctly measure the oral suspension as prescribed.
The utility model discloses a vomit preventing and stopping acupoint patch and belongs to medical devices. The acupoint patch comprises an ointment, sterile gauze and a medical rubberized fabric or an adhesive sticker film. The vomit preventing and stopping acupoint patch comprises a patch body and a vacuum packing bag, wherein the outside of the patch body is coated with the vacuum packing bag. The patch body comprises the sterile gauze, a warmer pad heating sticker and the ointment, wherein the sterile gauze is coated with the warmer pad heating sticker, and the ointment is attached to the middle of the lower side of the sterile gauze. The lower side, at the periphery of the ointment, of the sterile gauze is coated with the medical rubberized fabric or the adhesive sticker film with a downward rubber surface, and the sterile gauze has 4 to 12 layers. The vomit preventing and stopping acupoint patch is used and operated simply, cannot fall off automatically to pollute patient clothes, and the curing effect is good. The vomit preventing and stopping acupoint patch is provided with a heating layer, so that the curing effect is further improved; and the patch can be widely used for preventing and stopping vomit after clinical chemotherapy.
PURPOSE: To describe the clinical presentation and urodynamic findings in detrusor underactivity (DU) patients and investigate the association between DU and straining related complications such as pelvic organ prolapse (POP), inguinal hernia, and hemorrhoids.
METHODS: We retrospectively reviewed all consecutive patients who underwent urodynamic studies (UDS) from 2012 to 2023, divided into two groups: those with evidence of DU (n = 573), and control subjects with normal voiding parameters (n = 522). Exclusion criteria were patients who lacked sufficient data, those with obstructive voiding parameters, and those who had received intravesical botulinum toxin injections within the previous nine months. Demographic information, clinical presentation, straining related complications, and UDS findings were compared between the two groups using univariate statistical analysis.
RESULTS: The male DU group had a statistically significant higher prevalence of spinal disease and previous cerebrovascular accidents, while the female DU group had a statistically significant higher prevalence of spinal disease, multiple sclerosis, diabetes, previous colorectal surgery, previous transabdominal gynecological surgery, POP surgery, and recurrent UTIs. Female DU patients had a higher prevalence of pronounced vaginal bulging symptoms, recurrent POP, inguinal hernia, and hemorrhoids. The predominant LUTS were voiding symptoms (81.2% in males and 77.9% in females), followed closely by storage symptoms (66.2% in males and 74.7% in females). The median Qmax, PdetQmax, and PVR were 6 ml/sec, 18 cmH2O, 190 ml for male DU patients, and 8 ml/sec, 11 cmH2O, and 200 ml for female DU patients, respectively.
CONCLUSION: Risk factors for DU that were identified include age, neurological diseases (spinal disease, CVA in men, MS in women), diabetes and transabdominal surgery (colorectal, gynecological) that can cause pelvic denervation in women. DU patients commonly present with both voiding and storage symptoms. There is approximately twice the risk of having POP surgery and inguinal hernia, an eight-fold risk of hemorrhoids, and a three-fold risk of recurrent UTIs for females. This is thought to be secondary to increased intra-abdominal pressure during urinary straining.
PCT No. PCT/RO81/00001 Sec. 371 Date Sep. 16, 1981 Sec. 102(e) Date Sep. 16, 1981 PCT Filed Jan. 21, 1981 PCT Pub. No. WO81/02106 PCT Pub. Date Aug. 6, 1981.A new process is disclosed for the preparation of a biologically active bee product under sterile conditions. In the process drone bee larvae, worker bee larvae or queen bee larvae are picked up before respective cell capping together with larval food contained in comb cells to form a mixture of crude larval triturate. The mixture is then triturated and filtered to remove impurities to yield the desired product. The product is useful as an animal feed and in the preparation of royal jelly.
The primary objective of this study was to evaluate the predictors associated with target concentration (non-)attainment of imipenem in critically ill patients. The secondary objective was to explore the correlation between achieving imipenem target concentrations and clinical outcomes of therapy. A retrospective cohort study was conducted in critically ill patients treated with imipenem. Clinical data were extracted from the patients' electronic medical records. The pharmacokinetic/pharmacodynamic target was defined as free imipenem concentrations above the minimum inhibitory concentration (MIC) of the pathogen at 100% (100%fT>MIC) of the dosing interval. Factors associated with the non-attainment of target concentrations were evaluated using binomial logistic regression. Kaplan-Meier analysis was used to investigate the correlation between (non-)attainment targets and 30-day mortality. A total of 406 patients were included, and 55.4% achieved the target of 100%fT>MIC. Regression analysis identified an initial daily dose of imipenem ≤ 2 g/day, augmented renal clearance, age ≤ 60 years, recent surgery, and absence of positive microbiology culture as risk factors for target non-attainment. Achieving the 100%fT>MIC target was significantly associated with clinical efficacy but not with 30-day mortality. Selective application of therapeutic drug monitoring in the early stages of imipenem treatment for critically ill patients can improve clinical outcomes. Further research should explore the potential benefits of TDM-guided dosing strategies for imipenem in critical care settings.
PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner.
Background:

Individualised treatment for tuberculosis (TB) to improve treatment outcome has still some substantial obstacles to pass before becoming a reality in clinical practice. Previous studies, including studies from the study research group, have shown that lower than recommended drug concentrations of TB drugs are common, and affect treatment outcome. Despite this, lower than recommended doses are often prescribed by clinicians. Adequate drug doses should be ensured as early as possible in the intensive phase when the bacterial load is high. Simple therapeutic drug monitoring (TDM) at the time of steady state of TB drugs are used in many clinical settings today, but time to dose adjustments to avoid suboptimal drug levels is typically several weeks. However, pharmacokinetic models are in place to guide individualised drug dosing by Model-Informed Precision Dosing (MIPD) already from the first days of treatment. MIPD, in combination with currently recommended dose recommendations, can be used to derive the most efficacious and safe dose for a patient. A similar approach has been implemented for dosing of vancomycin in children but has not been used in a clinical setting in the field of TB. This study will evaluate the logistics and dose regimens when clinicians are given the current dose recommendations of the first line drugs rifampicin, isoniazid and pyrazinamide, as well as the results of the MIPD, for patients with active pulmonary TB.
Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit. Physicians also receive a free dermatoscope with instructions for uploading images of suspect lesions and attend a 30-minute online course comprising additional descriptions of dermoscopic images for skin cancers and "mimickers" common in hematopoietic stem cell transplantation patients, along with clear instructions for using a dermatoscope and steps to integrate dermoscopy into their practice.
<P>PROBLEM TO BE SOLVED: To provide a new system which supplies a transfusion medicine to a patient.  <P>SOLUTION: A system and a method, which automatically supply a transfusion medicine to a patient, are disclosed. A transfusion feed system 10 includes a transfusion set 12 and a transfusion device 14. A signal parameter arranged in a transfusion set parameter identifies the administration protocol of the transfusion set 12. A detector operably connected to the transfusion device 14 detects the signal parameter and identifies the administration protocol. After that, the transfusion device 14 is set so as to operate according to the administration protocol. A transfusion tube 24 for supplying the transfusion medicine 28 to the transfusion device 14 extends from a transfusion medicine source 22 to the transfusion device 14.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Statin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (CoA) reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis. Statins reportedly target the immune microenvironment through cytokines or chemokines and immune checkpoints. In a B16 melanoma lung metastatic model, statin lowers PD-1 expression in CD8+ T cells and effectively restores antitumor activity. In colorectal cancers model, simvastatin acts as a potential therapeutic drug for immunotherapy, which suppresses lncRNA SNHG29-mediated YAP activation and promotes anti-tumor immunity by inhibiting PD-L1 expression. Some retrospective observational studies have reported that baseline statin use was associated with improved clinical activity of PD-1/PD-L1 inhibitors in non-small cell lung cancer (NSCLC) patients. These findings support the adjuvant role of statins combined with immunotherapy. Statin therapy may be a combination tool for cancer immunotherapy in patients with NSCLC. Data from already completed clinical trials are not always supportive. These findings should be validated in further prospective studies with larger sample sizes. More clinical trials are needed to explore the right drug type, dose, frequency, duration, and suitable participator. Thus, this prospective observational study was designed to evaluate the safety and efficacy of PD-1/PD-L1 inhibitors in combination with statins compared with treatment with PD-1/PD-L1 inhibitors alone in advanced NSCLC patients.
Participants will eat four egg whites/day for 30 days. Participants will be given a specified number of Kieke eggs to last them until their next appointment. They will be asked to eat no other eggs than whites from the eggs given to them and to return cartons with any leftover eggs.
Participants first received Atorvastatin 40 mg tablets once daily for 6 weeks. After a washout period of 4 weeks, they then received placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks.
The present invention provides a cold-fever relieving liniment and the preparation method, which includes the raw materials with the following mix ratio by weight: 0.2 to 0.5 part of bupleurum grease, 0.2 to 0.5 part of saposhnikovia divaricata grease, 0.2 to 0.5 part of schizonepeta tenuifolia briq. grease, 0.2 to 0.5 part of mint volatile oil, 0.2 to 0.5 part of lecithin, 0.2 to 0.5 part of azone, 0.1 to 0.5 part of glycerol, 0.1 to 0.3 part of Tween-80 and 80 to 120 parts of ethanol. The method of the present invention is that the grease is extracted respectively from the schizonepeta tenuifolia briq. bupleurum and saposhnikovia divaricata; then the anti-inflammatory ingredients are extracted from the schizonepeta tenuifolia briq. and the bupleurum by using the ethanol solution, the bupleurum and schizonepeta tenuifolia briq. ethanol liquid is obtained by absorption and filtration; then the glycerol is added and mixed evenly; after that, the lecithin and azone are added into the bupleurum grease, saposhnikovia divaricata grease, schizonepeta tenuifolia briq. grease and the mint volatile oil to be ground and dissolved into the oily solution together; finally, the oily solution is added into the extraction liquid which is dissolved with the glycerol, Tween-80 is added in which and is mixed evenly to get the product.